Gelonghui, April 3 | Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (“Guangsheng Zhonglin”), an innovative pharmaceutical holding subsidiary of Fujian Guangshengtang Pharmaceutical Co., Ltd., has actively carried out patent applications on a global scale to provide intellectual property protection for innovative drug research and development since starting innovative drug research and development. Recently, Guangsheng Zhonglin obtained the following patent certificates or authorization notices for new drugs under development.

The compounds and morphology of the company's hepatitis B core protein inhibitor GST-HG141 (generic name: nericavir) have applied for international patents through the PCT channel. Up to now, it has obtained a total of 30 relevant international patents in 30 countries or regions (including this one).

The compounds and morphology of the novel c-Met targeting drug GST-HG161 have applied for international patents through the PCT channel. Up to now, 34 countries or regions have obtained relevant international patents (including this one).